Priest KC, Gorfinkel L, Klimas J, Jones AA, Fairbairn N, McCarty D Comparing Canadian and United States opioid agonist therapy policies Int J Drug Policy PubMed

Gorfinkel L, Giesler A, Dong H, Wood E, Fairbairn N, Klimas J Development and evaluation of the Online Addiction Medicine Certificate: free novel program in a Canadian setting JMIR Med Educ PubMed

Klimas J, Gorfinkel L, Fairbairn N, Amato L, Ahamad K, Nolan S, Simel DL, Wood E Strategies to identify patient risks of prescription opioid addiction when initiating opioids for pain: a systematic review JAMA Netw Open PubMed

Klimas J, Gorfinkel L, Giacomuzzi S, Ruckes C, Socías ME, Fairbairn N, Wood E Slow release oral morphine versus methadone for the treatment of opioid use disorder BMJ Open PubMed

McEachern J, Adye-White L, Priest KC, Moss E, Gorfinkel L, Wood E, Cullen W, Klimas J Lacking evidence for the association between frequent urine drug screening and health outcomes of persons on opioid agonist therapy Int J Drug Policy PubMed

Gorfinkel L, Klimas J, Reel B, Dong H, Ahamad K, Fairgrieve C, McLean M, Mead A, Nolan S, Small W, Cullen W, Wood E, Fairbairn N In-hospital training in addiction medicine: a mixed-methods study of health care provider benefits and differences Subst Abus PubMed

Gorfinkel L, Voon P, Wood E, Klimas J Diagnosing opioid addiction in people with chronic pain BMJ PubMed

Gorfinkel L, Wood E, Klimas J Prescription opioids, opioid use disorder, and overdose crisis in Canada: current dilemmas and remaining questions Can J Addict Link

Moss E, McEachern J, Adye-White L, Priest K, Gorfinkel L, Wood E, Cullen W, Klimas J Large variation in provincial guidelines for urine drug screening during opioid agonist treatment in Canada Can J Addict Link